Calidi Biotherapeutics, Inc.
CLDICalidi Biotherapeutics, Inc. (CLDI) is a biotechnology company focused on developing advanced cell-based immunotherapies for cancer and infectious diseases. The company leverages proprietary platform technologies, including its tumor-targeting and immune-activating cell systems, to create innovative treatments aimed at improving patient outcomes.
Company News
Calidi Biotherapeutics announced it received positive pre-IND feedback from the FDA for its lead candidate CLD-401, an oncolytic virus with IL-15 superagonist delivery. The company plans to submit an IND application by end of 2026 and initiate first-in-human clinical trials in early 2027. The FDA alignment on CMC, non-clinical programs, and clini...
Calidi Biotherapeutics disclosed that its 2025 annual financial statements include an audit report with a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations. The company is advancing its RedTail platform for genetic medicine delivery, with lead candidate CLD-401 in IND-enabling stu...
Calidi Biotherapeutics completed a $6.0 million underwritten public offering, selling 12.1 million shares of common stock along with Series J, K, and L warrants. Ladenburg Thalmann & Co. Inc. served as sole book-running manager. The warrants have exercise prices of $0.50 per share with varying expiration terms and include reset provisions.
Calidi Biotherapeutics announced an underwritten public offering of units consisting of common stock and warrants, with Ladenburg Thalmann & Co. Inc. as sole book-running manager. The company intends to use net proceeds for working capital and general corporate purposes. The offering is subject to market conditions and there is no assurance as to...
Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform, which enables systemic delivery of bispecific T-cell engagers (BiTEs) and IL-15 superagonist directly to solid tumors. The approach aims to overcome BiTE limitations in solid tumors by remodeling the tumor microenvironment and activating T-cells. The company is...
